Specify Company / Ticker to Get the Summary
Adial Pharmaceuticals Inc
ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia. Address: 4870 Sadler Road, Glen Allen, VA, United States, 23060
Analytics
WallStreet Target Price
7.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ADIL
Dividend Analytics ADIL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ADIL
Stock Valuation ADIL
Financials ADIL
Results | 2019 | Dynamics |